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Executive Summary 
 Drug testing is used in a number of contexts in Australia and internationally. These uses 
include providing medical information within drug treatment, helping inform legal 
decisions, roadside drug testing, and detecting drug use among specific populations, such 
as in workplaces and schools.  
 The aims which drug testing programs are proposed to meet, the rationale for their use, 
evidence of their effectiveness for meeting their aims, their other potential 
consequences, and the ethical and legal issues they invoke, all differ by context. 
 Drug testing programs impose a burden on those tested, in terms of their infringement 
on individuals’ bodily and information privacy. For a specific drug testing program to be 
acceptable, this burden must be outweighed by relevant factors present in the specific 
context of use. Such factors may include considerations of public safety or other 
significant public interests, or the consent of those undergoing testing. 
 This paper focuses on drug testing as used within drug treatment, among parents in 
contact with child protection services, in schools, among welfare beneficiaries, and in the 
workplace.  
 With regard to each of these contexts, the paper overviews the rationale for using drug 
testing or implementing a program of drug testing, the coherence of the rationale, the 
current evidence base for the use of drug testing in that context, and the ethical or legal 
issues raised. 
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 Within drug treatment, drug testing is primarily used in Australia to support medical decision-
making. This is a valid medical usage to ensure that prescribed treatments will be safe and effective 
for patients. There is, however, a need to ensure that such testing does not outrun its medical use, 
and is used only to review and improve the individual’s progress in treatment. 
 Regarding parental drug testing to facilitate child protection decisions, drug tests may provide 
further information on particular families’ situations. It is important that the use of drug testing in 
this context is cautiously considered. Where decisions to use drug testing are made within 
particular cases the information they provide should be considered supplementary to other 
information on the family situation. The possibility of false negatives or false positives needs to be 
carefully considered and addressed. 
 There is little satisfactory evidence to support the use of drug testing in schools, but there are 
reasons for concern about potential negative effects and high costs, and evidence of other, non-
intrusive methods that might better meet the aims of such drug testing programs. There should be 
a presumption against the use of drug testing programs in schools on the currently available 
evidence-base.  
 There is no evidence that drug testing welfare beneficiaries will have any positive effects for those 
individuals or for society, and some evidence indicating such a practice could have high social and 
economic costs. In addition, there would be serious ethical and legal problems in implementing 
such a program in Australia. Drug testing of welfare beneficiaries ought not be considered. 
 The evidence for the effectiveness of workplace drug testing programs to improve workplace 
safety is limited. There is potential for negative consequences for companies as well as employees, 
including high economic costs; and some evidence that other measures would be more likely to 
improve workplace safety. In addition there are problematic ethical and legal implications 
surrounding employee privacy. While the ANCD recognises that a stronger rationale and argument 
for drug testing of workers in safety-sensitive positions, or in positions of public trust and 
authority, can be given, there should be a presumption against a broader introduction of 
workplace drug testing. 
 Drug testing programs are highly expensive. For example, the cost of implementing drug testing 
programs in Australian schools has been estimated be up to $355 million. A program of drug 
testing welfare beneficiaries which operated for four months in Florida, USA, and discontinued 
benefits to those who tested positive, cost the state an estimated $118,140, and ran at a net loss 
of approximately $45,000. Drug testing programs are unlikely to have any economic benefits in 
most contexts. 
 Whilst it is understandable why some might presume that drug testing is a useful strategy, it is high 
in cost, may have unintended adverse outcomes, and raises serious ethical and legal issues. Its 
drawbacks may be addressed, at least in part, if it is clearly demonstrated that drug testing 
effectively meets its aims and reduces risk. At least to date, however, the evidence does not 
support such a conclusion. 
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Introduction 
Drug testing is used in a variety of settings in Australia and internationally. The aims of performing 
drug tests differ greatly by context, but include deterring drug use among specific populations, 
ensuring workers in safety-sensitive positions are not drug-impaired, screening particular 
populations in order to refer people who use drugs to treatment or other interventions, and 
supporting the decision-making processes of courts or state agencies.  
Drug testing does, however, impose a burden on those tested. Undergoing a drug test can be 
invasive; it can violate individuals’ bodily and information privacy; and many people experience it as 
humiliating or dehumanising. There is little to no evidence from controlled investigations that it is 
effective in meeting its aims in many of the settings in which it is used. Drug testing programs are 
often very expensive, and concerns have been raised about potential negative consequences. 
The Australian National Council on Drugs (ANCD) is aware of the continuing calls to introduce drug 
testing programs in various settings, and has developed this position paper to examine the costs and 
benefits of drug testing, and drug testing programs. The ANCD supports evidence-based practice, 
and recognises the need for interventions introduced to be ethically acceptable, minimally intrusive, 
and developed consistently with best practice.  
In considering whether and in what situations drug testing is acceptable, appropriate, or advisable, a 
number of factors need to be considered, and their relevance differs by context. These include, but 
are not limited to: the purpose of the drug testing; whether there is satisfactory evidence that drug 
testing is likely to fulfil this purpose; how people are selected to be tested; other (negative or 
positive) effects; the accuracy of testing technologies used; the availability of other methods for 
fulfilling the relevant purposes; and costs and cost-benefit ratios. Consideration also needs to 
recognise that since testing imposes a burden on those tested, the outcomes of testing should be 
sufficiently important to compensate for or outweigh this burden.  
This ANCD paper focuses discussion on the use of drug testing in the contexts of drug treatment 
programs, child protection, people receiving welfare benefits, schools, and workplaces. The 
discussion examines features of these contexts relevant to the acceptability, appropriateness, and 
advisability of drug testing programs within each context. Before discussion of each specific setting, 
we provide background information on drug testing technologies and programs, and a brief 
discussion of some ethical and legal issues. 
In reviewing Australian and international evidence relating to drug testing, the ANCD concludes that 
widespread adoption of drug testing should not occur, unless or until a stronger evidence-base 
emerges supporting its effectiveness, and there is information on how potential adverse outcomes 
and ethical difficulties can be addressed. A precautionary principle should prevail with regard to the 
introduction of any new drug testing programs. The ANCD acknowledges that there are reasons to 
use drug testing in some situations, such as for medical reasons related to treatment; and that a 
stronger argument for the use of testing can be given in other situations, such as roadside drug 
testing, or drug testing of workers in highly safety-sensitive positions. In cases such as the latter, 
drug tests should be one component of broader, rehabilitation-focused strategies to address 
potential harms arising from workplace drug use.  
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Drug testing technologies and programs1 
Drug tests can be performed on samples of the blood, breath (currently alcohol only), urine, saliva 
(more precisely, oral fluid), hair, and sweat. The methods differ in their windows for detection of 
drug ingestion. Hair and sweat testing are generally used to detect use over a period of weeks or 
months. Urine tests detect use during previous days or weeks, depending on the type of substance, 
while oral fluid testing detects use within a shorter period of hours or days. Table 1 provides 
indications of typical detection windows for different drugs according to one large Australian 
laboratory.  
 
Testing may be undertaken on-site using ‘point-of-collection testing’ (POCT) devices, or samples may 
be sent to a laboratory for analysis. In general, POCT devices are less expensive and provide more 
timely results, while laboratory analysis is more accurate and can better distinguish illicit from 
prescription drug use. These methods can also impact on detection windows (see Table 1).  
These timeframes may have implications for the appropriateness of various drug testing programs. 
For instance, oral fluid testing has been endorsed in several industrial tribunal decisions as the most 
appropriate technique for workplace testing programs, because its shorter detection window is 
regarded as meaning it is more likely to overlap with impairment from drug use (for example, Shell 
Refining (Australia) Pty Ltd vs CMFEU; Endeavour Energy vs Communications, Electrical, Electronic, 
Energy, Information, Postal, Plumbing and Allied Services Union of Australia and others). Hair or 
sweat testing is used in some settings overseas where information on longer-term use patterns is 
sought, such as among parolees or for parental drug testing by child protection agencies.  
It is worth emphasising that although matching drug testing method detection windows with the 
intended purpose of drug testing is a valid consideration, drug tests do not measure impairment. 
Tests detect the presence of a drug or its metabolites in a sample. This is distinct from measuring 
impairment and, in general, there is no way precisely to map drug test results onto impairment. The 
only exception in this regard, at present, is breath testing for alcohol, as the strong evidence base 
                                                          
1
 For more detail on topics in this section see Pidd and Roche (2011). 
Table 1: Windows of detection by drug type and testing method 
Drug Urine test 
On-site 
Urine test 
Lab-based 
Oral fluid test  
On-site 
Oral fluid test 
Lab-based 
Cannabis (THC) 
Infrequent use 
Chronic Use 
 
Up to 10 days 
30 days or longer 
 
Up to 10 days 
30 days or longer 
 
Less than 24 hrs 
Less than 24 hrs 
 
Less than 24 hrs 
Less than 24 hrs 
Opiates 2-4 days 2-4 days Less than 24 hrs 0-3 days 
Amphetamines 2-5 days Up to 2 weeks Less than 24 hrs 0-3 days 
Cocaine 2-3 days 2-3 days Less than 24 hrs 0-3 days 
Methamphetamines 2-5 days 2-5 days Less than 24 hrs 0-3 days 
Benzodiazepines Up to 2 weeks Up to 2 weeks Less than 24 hrs 0-3 days 
Source: Medvet Laboratories (2012) 
5 
 
allows a conclusion that a blood alcohol content of 0.05mg per cent or higher indicates impairment 
(Pidd et al. 2011a). But for other substances, amounts ingested or the times at which it was ingested 
cannot be inferred, and many substances remain detectable long after the primary impairing effects 
have dissipated. There is no scientific agreement on what level of use would indicate impairment, 
and for some substances it is unlikely that such levels could be determined given the differing effects 
on individuals. Nor do drug tests provide information on whether or how a person’s drug use has 
problematic effects on other aspects of their lives, or whether he or she is drug dependent. This 
limitation was well summarised more than 25 years ago by the US Council on Scientific Affairs:  
Drug testing does not provide any information about patterns of drug use, about abuse 
of or dependence on drugs, or about mental or physical impairments that may result 
from drug use. (Council on Scientific Affairs 1987) 
Any method of drug testing may result in false positives (incorrectly determining drug use has 
occurred) or false negatives (incorrectly determining drug use has not occurred). Testing devices and 
technologies are assessed in terms of their sensitivity (the proportion of positive samples correctly 
identified as such), specificity (the proportion of negative samples correctly identified as such), and 
accuracy (a combination of sensitivity and specificity). Pidd and Roche (2011) discuss several recent 
evaluations of drug testing devices and laboratories, which found widely differing levels of 
sensitivity, specificity, and accuracy among different commercial testing devices and for different 
substances. In a study focusing on urine POCT devices, for example, “accuracy for amphetamine 
detection varied from 66% to 100%, sensitivity from 16% to 100%, and specificity from 56% to 100% 
across urine devices. For cannabis, accuracy varied from 85% to 97%, sensitivity from 70% to 99%, 
and specificity from 90% to 100% across urine devices” (Pidd and Roche 2011). Laboratory testing, 
which is necessary to confirm any positive test according to Australian standards, is generally more 
accurate, but nor is it exact. One recent study which re-analysed testing samples in a large US 
hospital found there had been an error rate of 12 per cent (Pidd and Roche 2011).  
Drug testing programs may be implemented in a number of ways, which can impact on their 
appropriateness in different contexts. Testing of a particular population (such as in the workplace, or 
of school students) may randomly select individuals, or be imposed on all individuals. Or testing may 
be targeted to individuals who meet particular criteria. For instance in workplace testing programs, 
testing may target those in safety-sensitive positions, or people who have been involved in 
accidents. Many school drug testing programs in the USA target students who are involved in 
athletics or other extra-curricular activities. Or, in some instances, testing will target those who are 
thought for other reasons to have problems with drugs or alcohol, as may occur in testing of parents 
engaged with child protection services.  
 
Ethical and legal issues 
This section provides a brief outline of the conceptual framework used in this paper to consider the 
ethical and legal issues involved with drug testing. We begin by recognising that drug testing 
imposes a burden on those individuals who undergo it. This burden is at least partly, and perhaps 
largely, constituted by a violation of those individuals’ privacy. Drug testing violates privacy in the 
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senses of individuals’ bodily privacy, and privacy of information.2  
The right to privacy has been argued to be central to the fundamental values of liberal democracies, 
and legal analyses have derived privacy rights from commitments to democratic principles in 
Australia (Roche et al. 2008). Ethical analyses have also indicated the central role of privacy in 
democratic societies: respect for privacy has been analysed in terms of recognition of and respect 
for personhood; respect for individual agency; and the capacity of individuals to maintain their 
various relationships with others (Rachels 1975; Benn 1980; Reiman 1976). Bodily and information 
privacy are protected by law in Australia, including by laws relating to information privacy, assault 
and trespass, and defamation (Roche et al. 2008).  
In recognising that drug testing does involve a violation of privacy, the ANCD also acknowledges that 
individuals’ privacy rights are routinely regarded as being overridden by other concerns in various 
situations, and that our expectations of privacy differ by context. For instance, particular individuals’ 
right to privacy is overridden in some situations by the needs of public safety. This explains, for 
example, why random drug and alcohol testing of drivers is acceptable;3 and why drug testing of 
airline pilots (and others in safety-sensitive positions) is more acceptable than of other employees.  
The expectation that one can keep certain information private may thus be lowered or absent in 
situations where there are important interests at stake which conflict with this – and this may 
include interests other than public safety. For instance, withholding evidence in criminal enquiries, 
against the interests of justice, is not considered reasonable, even if divulging such evidence involves 
divulging information that would normally be considered private. Another example is people who 
hold positions of authority and public trust, who may reasonably be expected to relinquish their 
privacy to some extent or in some respects. Such ‘role-specific’ factors can sometimes override the 
right to privacy, which may explain why drug testing of police, correctional workers, or customs 
officials is often regarded as more acceptable than of other workers (see Prenszler 2006).  
In some contexts, consent to being tested may also be ethically relevant (though nor should we 
consider consent a justificatory ‘catch-all’). This may be another part of the reason that expecting 
law enforcement officials to submit to drug testing is more generally accepted than testing of other 
workers, since people in these kinds of employment could be regarded as having given de facto 
consent to lowered privacy in virtue of their employment decisions. Similar considerations may 
apply to drug testing of elite sportspeople.  
These examples show that, even though drug testing infringes upon privacy, this does not imply that 
it is never acceptable. Rather, it implies that when considering any proposal to perform drug tests in 
some particular context, we need to consider what feature or features of that context could justify 
that infringement. The most usual, and perhaps most compelling, considerations in this regard likely 
relate to public health and safety, but there are other considerations which may be compelling in 
                                                          
2
 The testing situation itself can also be experienced as intrusive, particularly for urine testing, as urine samples 
may need to be given under supervision. Concerns have been raised about gender and cultural sensitivity of 
these supervision situations, as well as the potential for sexual misconduct. 
3
 Whilst the ANCD acknowledges the acceptability of random roadside drug or alcohol testing, it should also be 
noted that the evidence base for testing for drugs other than alcohol is less robust, and that there are no 
agreed levels at which the presence of other drugs indicate impairment. 
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some contexts and not in others.  
Of course, the ethical acceptability of imposing drug testing onto a particular group of people does 
not only depend on the presence or absence of such justifying factors, since as we have recognised, 
it does constitute a burden and an infringement on privacy rights. That is, even where drug testing is 
ethically and legally justifiable, it may not necessarily be advisable. As such, the ethical acceptability 
of drug testing is also affected by the evidence on how likely such tests are to meet their aims, the 
extent and nature of unintended adverse outcomes and, importantly, whether there are other 
methods which could be used to meet those aims and which would not involve an infringement of 
individual rights.  
In the following sections we examine the use of drug testing in different contexts, with differing 
aims, rationales, evidence of effectiveness, potential positive and negative effects, and particular 
ethical and legal issues. 
 
Drug testing in drug treatment 
Drug testing is used in some drug treatment contexts; in Australia this primarily applies to people on 
pharmacotherapy programs. The aim of such testing is to obtain information to support medical 
decision-making. That is, clinicians use drug tests to establish uptake of prescribed medication and 
the presence of any non-prescribed drugs in a patients’ system. This testing provides information 
relevant to ensuring that the treatment regimes prescribed will be safe for patients and best meet 
their medical needs.4   
Some international studies have examined another use for drug testing in treatment contexts, 
involving linking negative test results to rewards, or positive test results to punitive measures, as a 
way to support treatment aims. There is a strong evidence base for positive reinforcement through 
linking treatment adherence to rewards (also known as ‘contingency management’) (Hartzler et al. 
2012). Punitive uses, where drug test results are linked to negative outcomes, however, may not 
have positive effects in the long term (Defulio et al. 2009). The punitive and coercive nature of such 
programs can imply a lack of trust in the patient, which can have its own consequences. The ANCD 
does not support widespread adoption of such punitive uses, noting their limited efficacy coupled 
with the potential for serious negative consequences for individuals in such approaches.  
Australia’s pharmacotherapy guidelines recognise this lack of evidence, and state that drug testing of 
people on pharmacotherapy programs should only be used for medical purposes; it is not to be used 
as a deterrent or linked to punitive measures. The National Pharmacotherapy Policy5 states: 
Urine testing should only be undertaken with good reason, such as in the initial 
                                                          
4
 Drug testing is also undertaken to assess the efficacy of some treatments for reducing use of illicit drugs or 
assess treatment compliance in the context of research. This will not be addressed in this paper as such use 
falls under research regulations. It may also be used in research contexts to confirm confidence in self-report. 
There has been some criticism of this use as it appears to assume that research participants are not truthful, 
and there is inconsistent evidence about whether it adds evidentiary value. 
5
 Most jurisdictional documents either repeat this advice, or refer to the national policy. 
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assessment of an individual, to confirm the clinical history or as part of program 
evaluation. Urine testing can also be useful when clients are unstable (such as in the early 
stages of pharmacotherapy treatment) and when there is some uncertainty about their 
drug use. There is little evidence to support the use of urine drug monitoring as a 
deterrent against unsanctioned drug use. Test results should be used, in collaboration 
with the client, to review and improve the individual’s progress in treatment. (Australian 
Government Department of Health and Ageing 2007) 
The current Clinical Guidelines and Procedures for the Use of Methadone in the Maintenance 
Treatment of Opioid Dependence, a national document produced by an expert committee, repeats 
these points, adding that “Methadone programs should not be punitive”. It also clarifies that 
although Medicare allows for 21 urinalysis tests6 per patient per year, “It is expected that the 
average number of tests will be significantly lower than this maximum and will decrease the longer a 
patient has been in treatment” (Henry-Edwards et al. 2003). 
Despite this, patients may be asked by the prescriber or provider of a pharmacotherapy to provide a 
test sample at their discretion, and the use of tests may at times not conform to these guidelines. If 
testing is overused, an unnecessary burden is placed on individuals in treatment (and there are 
additional unnecessary costs for the health system). There are also indications that people on 
pharmacotherapy programs are not always properly informed of the purpose of drug testing or what 
will happen to the results. Where this purpose is, or is misunderstood as, surveillance or 
punishment, this could affect treatment uptake or have other undesirable effects on treatment 
engagement, retention, and effectiveness of programs. While drug testing can provide important 
medical information to clinicians, testing should be limited to that which is needed for treatment in 
line with national policies and guidelines, and care needs to be taken in making the purpose of any 
testing undertaken transparent to those tested. 
 
Drug testing and child protection services 
Drug tests are sometimes used among parents of children who are considered ‘at risk’ by child 
protection agencies. In Australia such testing is not broadly used, and usually occurs in relation to 
decisions by child protection agencies to remove or restore a child to his or her parents, where the 
parent has some history of drug problems. Again, the aim of these tests is to facilitate decision-
making. Drug testing may provide additional information on parental drug use that could be relevant 
to a child’s welfare (Moller et al. 2010). The rationale for seeking to assess drug use is that people 
who are using drugs may be less able to care for children; a significant proportion of substantiated 
child protection cases have been found to involve drug or alcohol problems (Scott 2002). A second 
aim of programs in some locations (such as Canada, see Fraser (2001)) is to help families stay 
together in the longer term, or improve overall parenting, through identifying parents who have 
drug or alcohol problems and referring them to treatment. Some have also suggested that drug 
testing could form part of an approach which uses improving one’s parenting capacity as a motivator 
                                                          
6
 The current (April 2013) number available per year is 36, though this is subject to change (personal 
communication, Department of Human Services, 11 April 2013).  
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to address alcohol or drug problems (Famularo et al. 1988). 
Current Australian policies have drawn on a 2006 study undertaken by National Drug and Alcohol 
Research Centre (NDARC) researchers into the costs and utility of parental drug testing in child 
protection (Wood et al. 2006). This study recognised that although there are established correlations 
between parental drug or alcohol problems and child neglect or maltreatment, there is no clear 
causal link between the two. It is important to remember that parents with drug or alcohol problems 
do not necessarily have lower parenting capacity than others (Testa and Smith 2009). Furthermore, 
drug test results do not identify problematic drug use. They provide biological information at a 
particular point in time, but without contextual information on any drug use detected, or on other 
issues that may be present. The potential for false negative or false positive assessment of risk based 
solely on drug tests is evident. 
Evidence surrounding whether parental screening or treatment for alcohol or drug problems linked 
to drug testing programs reduces the likelihood of future child maltreatment or neglect, or aids 
children in other ways, does not provide clear guidance. Though some studies have indicated 
positive effects for children and families, there are some conflicting findings (with some studies 
actually reporting a negative effect on children of parental drug or alcohol treatment) (Testa and 
Smith 2009). A complication in such research is that among the parents of children engaged with 
child services who have drug or alcohol problems, a number of other factors may be present that are 
also risk factors for child neglect or maltreatment. These include low education levels, mental health 
problems, poverty, domestic violence, and social isolation (Scott 2009; Testa and Smith 2009). As 
such, addressing drug or alcohol problems while neglecting other difficulties experienced by families 
may have limited results.  
Nonetheless, as the NDARC study acknowledged, in some cases, drug use can impact negatively on 
parenting capacity, and this is more likely in cases where there is heavy, frequent use or dependence 
(Wood et al. 2006). In line with such considerations, as well as detailed analysis of research results, 
Wood and colleagues (2006) concluded that drug testing may be of use in cases where there is 
reasonable suspicion of drug use, but that blanket parental drug testing by child protection services 
would be of limited use. Blanket testing would also have the potential for negative consequences, 
such as undermining relationships between families and case-workers. Drug testing should therefore 
be considered on a case-by-case basis, as part of a broader strategy, but not routinely undertaken, 
nor uniquely relied upon. The report also provides a number of recommendations for best practice, 
including repeated tests over a period of time (to detect patterns of drug use more likely to affect 
parenting). It is important that this information is regarded only as one source of information among 
others of family contexts and circumstances, not as a sole basis for decision-making. Given the lack 
of evidence that parental drug testing programs are effective for their aims, the ANCD believes that 
use of drug testing should be cautiously considered case-by-case, until further evidence is available. 
In regard to using drug tests as motivators to reduce or cease use, via a linkage to the motivation to 
look after one’s children, it is important to note that drug testing itself does not reliably reduce drug 
use (Wood et al. 2006). Whilst the powerful motivation to keep one’s children might potentially be 
harnessed in ways that are beneficial to children, as well as their parents, the use of drug testing in 
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the development of this idea into a workable and effective program has not been demonstrated.7 
Since the removal of children from parents can be devastating for all parties, with significant long 
term effects, further research on how parents with drug or alcohol problems can be supported in 
treatment is worthwhile. There is also a documented need for more family and child sensitive 
alcohol and drug treatment services, and further integration of child services and adult alcohol and 
drug services (Scott 2009). Whether drug testing, or other interventions or screening methods, could 
play a role in such support is one question within broader issues which require a more developed 
evidence-base. 
 
Drug testing in schools8 
Random drug testing of school students has occurred in Russia, the Philippines, and in independent 
boarding schools in Britain (Gerada and Gilvarry 2005; DuPont et al. 2013). In Europe some schools 
have used ‘for-cause’ testing, i.e. testing of students who are suspected for other reasons to have a 
drug use problem. In the USA, about a quarter of school districts are thought to have student drug 
testing policies and half to test student athletes, and random testing of athletes and others engaged 
in extra-curricular activities has been found reasonable by the US Supreme Court (DuPont et al. 
2013). In Australia, drug testing has been introduced by several private schools. 
The aim of such testing is to improve the health and wellbeing of young people by identifying drug 
problems. As the value of early interventions in drug use problems has been shown, testing is usually 
regarded as a screening mechanism, enabling those testing positive to be referred to appropriate 
treatment or interventions (Roche et al. 2008). It has also been argued that drug testing programs 
could act as a deterrent to drug use initiation, and provide students with a way to resist peer 
pressure to try drugs (Roche et al. 2008).  
Issues with this rationale include that the deterrent power of drug testing (and the proportion of 
students who use drugs who experienced peer pressure) are not known; and that drug tests can 
often be evaded (depending on how programs are implemented), or samples substituted or 
manipulated (Roche et al. 2008). It is also important to note that the proportion of school students 
who regularly use drugs may be too low for random testing to identify any significant proportion of 
drug users (Roche et al. 2008). In the most recent Australian Secondary Students Alcohol and Drug 
Survey, while 15 per cent of students aged 12–17 had tried cannabis in their lifetime, few of these 
were counted as regular cannabis users (using cannabis more than 10 times in the previous year): 
4.6 per cent of males and 2.7 per cent of females were regular users. Rates for other illicit drugs 
were much lower. Lifetime use was reported as 3 per cent for hallucinogens, 3 per cent for 
amphetamines, 2 per cent for opiates, 2 per cent for cocaine, and 3 per cent for ecstasy; but 
proportions of those using these drugs regularly were all indicated to be less than 1 per cent (White 
and Bariola 2012).  
                                                          
7
 See Dawe et al. (2003) for detail on the Parents Under Pressure program, which can be described as utilising 
this idea, but which does not involve the use of drug testing.  
8
 This section draws heavily on a comprehensive report on this topic published by the ANCD in 2008, Drug 
Testing in Schools: Evidence, impacts and alternatives, undertaken by researchers at the National Centre for 
Research and Training on Addiction (Roche et al. 2008). See the report for more detail on this topic. 
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The evidence surrounding drug testing in schools is overall of low quality, and results are not 
consistent (Roche et al. 2008). Declines in drug use were reported in some schools with drug testing 
programs. These reports generally relied on the number of positive tests declining over time, 
however, and this may have had other causes for which studies did not control. These include the 
presence of other interventions introduced alongside testing, and increased test evasion or sample 
substitution by students. Other studies have found no correlation between testing and reduced drug 
use. Roche and colleagues concluded that “there are no sound research data to provide evidence of 
its effectiveness” (2008). 
In addition, concerns have been raised about potential negative consequences of drug testing of 
school students, although it should be noted that clear evidence on the probability or extent of 
these consequences is also lacking. Students may have to reveal other medications they have been 
prescribed, which involves a breach of confidentiality. There is the potential to divert students into 
use of other drugs (such as new synthetic drugs) which are not tested for or are less likely to show 
on tests, but may be more harmful – or to divert students from illicit drug to alcohol use (Roche et 
al. 2008). Many students find the experience of being drug tested distressing, and this could affect a 
much broader population than that affected by drug use problems. The distrust of students shown 
by random testing may be detrimental to the learning environment; impact on student-teacher (or 
even child-parent) relationships negatively; create a negative school environment; or make any drug 
use more secretive, discouraging students from asking for help (Roche et al. 2008). Overall, testing 
may increase disconnection from schools which, paradoxically, is a risk factor for alcohol and drug 
problems (as well as for other risky behaviours, depression, and poor health) (Roche et al. 2008). 
Drug testing may also identify people who have used drugs casually or experimentally, but do not 
have a dependence problem. This could in some cases transform such use into something more 
problematic, or be harmful in other ways (Gerada and Gilvarry 2005). 
Further, even though student drug testing is not intended to be punitive – indeed, this would 
undermine its stated aims – it may become so if implemented on a larger scale. In the USA, despite 
federal guidelines stating that student drug testing should not be used punitively, a large survey of 
how positive test results were dealt with by US public school districts found that (in addition to non-
punitive outcomes) 45 per cent notified law enforcement, 31 per cent suspended students from 
school, and 65 per cent suspended students from athletic programs (Ringwalt et al. 2009). Drug 
testing could thus contribute to increasing suspensions or expulsions, among those young people 
who are most in need of supervision. 
Drug testing programs of this kind are also very costly, and “likely to exceed most schools’ entire 
expenditure on drug education, prevention or counselling” (Gerada and Gilvarry 2005). Roche and 
colleagues developed a detailed cost estimate for different types of drug testing program in 
Australia. They estimated costs of between $12 million and $302 million using urine tests; or from 
$16 million to $355 million using oral fluid tests, per year or testing cycle for all schools (the lower 
figures are for ‘for-cause’ testing; the higher for testing whole school populations) (Roche et al. 
2008). In one US district, the drug testing program cost $35,000, and detected 11 drug using 
students (Gerada and Gilvarry 2005). 
Nonetheless, such programs continue to be introduced, and in the USA in particular much weight 
has reportedly been given by policymakers to several small, poor quality studies (Gerada and 
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Gilvarry 2005). The expansion of programs may also be partly driven by a high acceptability among 
parents (DuPont et al. 2013). Some private schools in Australia have introduced drug testing 
programs which operate with the consent of parents and/or students. Australian law does recognise 
children’s privacy rights more strongly than does US law. In the USA, children have lower 
expectations of a right to freedom from government interference (Roche et al. 2008). Australian law, 
in contrast, recognises limits to schools’ duty of care outside of school hours, and in case law it has 
been recognised that there are reasons to show trust to school students (including aiding their 
development). Australia also recognises the International Convention on the Rights of the Child, 
which states that a child should be free from “arbitrary or unlawful interference with his or her 
privacy” (cited in Roche et al. 2008). As such, any attempt to broaden drug testing of school students 
significantly in Australia is unlikely to be legally acceptable. Private schools who may be considering 
implementing a drug testing program should have access to information on the evidence and issues 
surrounding such programs, and program costs. 
In summary, there is little reason to conclude that drug testing in schools would meet its aims in 
supporting the health and welfare of young people. There is however reason to conclude that such 
programs would be high in cost and would invoke complex legal and ethical issues, and the potential 
for these programs to have negative effects for young people mandates caution. In addition, there 
are alternatives available for meeting the aims for which these programs are proposed. These 
include brief interventions and motivational interviewing; and improved, evidence-based school 
drug education programs. Unlike drug testing, some of these programs have been subject to 
rigorous evaluation and been found effective (Roche et al. 2008). We therefore conclude that there 
should be a presumption against the introduction of drug testing in schools, unless or until more 
satisfactory evidence can be offered, and the legal and ethical problems and potential for adverse 
effects addressed. 
 
Drug testing of welfare beneficiaries 
Drug testing of welfare beneficiaries has been proposed in a number of countries, including 
Australia. In the USA, a number of states have recently passed legislation enabling drug testing of 
welfare beneficiaries: Florida and Missouri in 2011; Arizona, Georgia, Oklahoma, Tennessee, and 
Utah in 2012; and Kansas and Texas thus far in 2013. This is despite the program in Florida having 
been challenged by the American Civil Liberties Union (ACLU) and ruled unconstitutional in a Federal 
District Court. In the United Kingdom, welfare beneficiaries may be required to undertake drug 
testing if they have breached other welfare conditions (such as undertaking job searches); a drug 
test can be ordered by welfare agency workers as part of larger programs which seek to increase 
employment participation by identifying and then removing barriers to work (Harris 2010).  
The aim of drug testing welfare beneficiaries is most often stated to be to identify people who use 
drugs in order to refer them to treatment, with the longer-term aim of increasing their capacity to 
find and maintain work. This can be regarded as part of broader trends in employment participation 
policies towards promoting the ‘active participation’ of welfare beneficiaries in seeking work. Some 
of the proposed programs make such treatment either mandatory or coerced, denying or limiting 
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benefits for those who do not take up or complete treatment. Other programs simply remove 
benefits from people who test positive or refuse to be tested. As such, another aim of drug testing 
welfare recipients is deterrence. In addition, such programs are sometimes proposed with the aim of 
protecting state funds from being used to finance drug use or maintain drug dependency, and 
reducing overall welfare spending.  
There is limited evidence available on the effectiveness of drug testing welfare recipients for 
deterrence of drug use, increasing employment participation, or reducing welfare spending. There 
are, however, several sources that are informative, or provide evidence indirectly bearing on these 
programs. First, some data is available on the program of drug testing welfare applicants in Florida, 
which operated for four months in 2011 before its enabling legislation was overturned. The ACLU 
has stated that of 4,086 people tested in this time, 108 (or 2.6 per cent) tested positive for drugs, 
most commonly marijuana. Forty additional people did not take the test. Under this program 
welfare applicants needed to pay for the test themselves initially, and those testing negative were 
then reimbursed by the state. The total cost to the state of the program was estimated to be 
$118,140 — around $45,000 more than the state would have paid in benefits to those whose 
benefits were discontinued after testing positive (Bloom 2012). Data on outcomes for those denied 
benefits, treatment referrals, and related matters are not available. 
An analysis of some indirect evidence relating to drug testing welfare recipients was developed by a 
group of Canadian experts in response to a policy proposed in Canada in the early 2000s. They 
argued that the policy, which involved mandatory drug testing linked to mandatory treatment, 
involved a “simplistic perspective of the nature of addiction”  (Giesbrecht and MacDonald 2001). The 
group recognised that there is evidence to suggest that treatment of people with drug problems 
could lead to better employment outcomes, and that mandatory treatment would likely increase 
treatment uptake. However, they also discussed flaws with the rationale for drug testing welfare 
recipients. First, they noted a lack of clear evidence that drug dependence, or drug use-related 
problems, are more prevalent among people on welfare than among the employed; indeed, a classic 
study estimated that in the USA about 70 per cent of people who use drugs were employed (in 
Giesbrecht and MacDonald 2001). In Australia, 25 per cent of unemployed people and 16 per cent of 
employed people reported using an illicit drug in the previous year in 2010 (Australian Institute of 
Health and Welfare 2011; see also Pidd et al. 2008b). Use in the previous year does not, however, 
clearly relate to having drug use-related problems, or to dependence. Although there is evidence 
that associates unemployment with drug use, particularly heavy or dependent use, this does not 
imply that any use of drugs will decrease employment capacities. In 2010, 14.7 per cent of 
Australians – around 3 million people – reported having used an illicit drug in the previous year, a 
much higher number than those whose employment capacities are affected by drug use. As such, 
there is no clear evidence that drug use in and of itself is a barrier to employment for a significant 
proportion of people – nor that it is a more significant barrier than other factors, such as transport 
problems, mental or physical health problems, or discrimination.  
Other issues with the above rationale are evident when we consider how any such program would 
operate. Since having used a drug does not in itself mean that a person’s employment capacities are 
affected by drug use, where drug testing of welfare beneficiaries did detect use, further clinical 
assessment would be needed before any action was taken. As well as adding to costs, this reminds 
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us that it is not appropriate for treatment decisions to be made by government workers or agencies 
that do not have relevant medical or specialist training (Giesbrecht and MacDonald 2001). 
There would also be reasons for serious concern about the negative consequences of denial of 
benefits on the basis of a positive test. Some studies undertaken in the USA indicate that denying 
benefits to people who are drug dependent could result in increases in poverty, crime, and 
homelessness, and in higher health and social costs. These are serious consequences both for 
individuals losing benefits, and for the general community. One study of people whose welfare 
benefits were discontinued when a decision was made to no longer count substance dependence as 
a disability reported worsening psychiatric comorbidities among this group (Giesbrecht and 
MacDonald 2001; see also Watkins and Podus 2000). This study also found that drug use levels 
remained the same over time among those who had lost their benefits. In comparison, among a 
control group of people who retained their benefits (due to the presence of another recognised 
disability), drug use levels fell from 75 per cent to 63 per cent. This undercuts the assumption that 
having welfare benefits could encourage drug use (Watkins and Podus 2000; see also Harris 2010). 
Finally, but importantly, such programs are highly problematic in ethical and legal senses. Even 
leaving aside arguments relating to welfare rights, making welfare payments conditional on 
abstinence from drugs is not a fair policy, because it does not plausibly take into account the 
commonality of relapse into drug use among people who are dependent. Such programs make 
assumptions about the nature of choice and drug use that do not fit with our knowledge of drug 
dependence. It is, perhaps, reasonable that welfare beneficiaries can expect some loss of privacy, 
such as in reporting details of their income and other personal details to welfare agencies. But the 
expectation that beneficiaries divulge such information (and meet other conditions such as 
undertaking job searches) is very different from a requirement to allow an invasion of bodily privacy 
using tests of a humiliating nature. This recognition is particularly important within a system in which 
it is important to promote resilience and empowerment among clients – but which, recent research 
has indicated, is already experienced as dehumanising, humiliating, and belittling to engage with for 
many people (Murphy et al. 2011). Such experiences can be particularly damaging to those 
experiencing drug use problems, and be counterproductive to treatment aims, as well as 
employment aims. The proposal to drug test this group is of serious concern as an additional 
imposition upon a segment of society that already bears so many burdens, and is heavily monitored. 
Furthermore, it is unlikely that such a policy could currently be legally instituted in Australia, as 
severe dependence on drugs has been recognised as a disability for the purposes of the Disability 
Discrimination Act 1992.  
Drug testing of welfare beneficiaries thus lacks evidence as a method to support employment 
participation or to reduce drug use or related harms. The small amount of (direct and indirect) 
evidence available seems to indicate that it is more likely to increase harms and costs, both to 
welfare beneficiaries and the general public, than it is to achieve its stated aims. The ANCD therefore 
believes that drug testing of welfare beneficiaries is based on a faulty rationale and incorrect 
assumptions about people who use drugs, the nature of drug dependence, and the effects of drug 
testing, and would emphasise that drug testing welfare beneficiaries is legally and ethically 
questionable.  
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Drug testing in the workplace 
In Australia, the practice of drug testing employees in the workplace primarily occurs within 
industries where work can be safety-sensitive, such as mining or transport. In some industries, such 
as aviation, drug testing of those in safety-sensitive positions is mandated by legislation. Police, 
correctional workers and customs officials may also be tested, and there have been proposals to 
expand testing to other occupations, such as teachers, nurses, or office workers within the mining 
and transport industries.9 
 
Aims of workplace drug testing 
The most usual aim of workplace drug testing programs in Australia is to improve workplace safety. 
As impaired workers may cause workplace accidents, injuries, and fatalities, identifying and 
removing impaired workers is a safety measure. Drug testing has also been proposed to improve 
safety through deterring drug use among workers. Organisations have clear interests in preventing 
such harms (which include but are not limited to their financial interests), and are obliged by 
workplace health and safety legislation to ensure the safety of their workers and the general public. 
In some cases, employee drug testing may also aim to ensure employee integrity or trustworthiness, 
most notably in the drug testing of law enforcement officials.  
A series of rulings by industrial tribunals, which have shaped Australia’s approach to workplace drug 
testing, have indicated that the above are appropriate aims of workplace drug testing programs. 
Such decisions have recognised that, even within industries where work may be safety-sensitive, 
employers should not attempt to detect drug use that occurs outside of work and has no impact on 
job performance: employers should not police their employees’ private behaviour, or seek to impose 
on them any particular moral or lifestyle choices10 (this does not apply to drug testing for the 
purpose of ensuring integrity for some kinds of positions; discussed further below). Nor is there a 
basis in Australia to drug test for the purpose of increasing productivity. This is partly because 
workers’ productivity can be (and in workplaces generally is) assessed by other means, and in any 
case drug tests do not provide direct information bearing on productivity. But it also reflects that 
such an aim is not one that could justify the infringement of privacy involved in testing (see 
Independent Inquiry into Drug Testing at Work 2004; Privacy Committee of New South Wales 1992). 
 
Prevalence and harms of workplace drug use 
                                                          
9 We do not consider drug testing in sport directly in this paper, as the drugs of concern, technologies used, 
and resources available for testing of elite sportspeople mean the issues are quite different. However, we note 
increasing uses of drug testing within club-level sports, and reports of increases in the use of performance-
enhancing drugs in the community, as issues of concern; and consider the issues surrounding drug testing in 
sports to partly overlap with those considered in this section. 
10
 In this regard, Australia differs significantly from the USA, where there is a legislative basis for testing purely 
for the purpose of ensuring that employees do not use drugs, in the Drug-Free Workplace Act 1990; 
comparisons with the USA may be part of the impetus for Australian programs, but the legal situation differs 
significantly. 
16 
 
Research on the extent of workplace and workforce drug use in Australia has been undertaken on a 
population scale at the National Centre for Education and Training on Addiction (NCETA), drawing on 
data collected in the National Drug Strategy Household Survey (NDSHS) every three years. In 
addition, a number of studies have investigated drug use within specific sectors or industries. 
Secondary analysis of data from the 2007 NDSHS found that: 
 the workplace was the usual location of alcohol consumption for 8.7 percent of workers; 
 the workplace was the usual location of illicit drug consumption for 0.9 percent of workers; 
 5.6 percent of employed respondents had attended work under the influence of alcohol in 
the previous year; and 
 2 percent of employed respondents had attended work under the influence of illicit drugs in 
the previous year. (Pidd et al. 2011b) 
Variables associated with using drugs at work or attending work under the influence of drugs 
included being young, male, never married, having no children, and using more than one drug (Pidd 
et al. 2011b). Some sectors and occupations also had significantly higher rates of drug use at work or 
attending work under the influence of drugs. Illicit drug use at work was most commonly reported 
by those in the transport (1.9 percent), construction (1.5 percent), and hospitality sectors (1.4 
percent). Alcohol use at work was most commonly reported in the hospitality (18.6 percent), 
financial services (14.7 percent) and services sectors (11 percent) (Pidd and Roche 2011). Other 
studies have raised concerns about drug use among transport workers, agricultural workers, and the 
‘fly-in-fly-out’ workforce, among others (for example see Pidd et al. 2008a; b; Davey et al. 2007; 
Mayhew and Quinlan 2006; Pedrana et al. 2008).  
There is some data available indicating that drug use is associated with increased absenteeism and 
lower productivity, and employer interest in drug testing programs internationally was partly 
stimulated by such evidence. Early estimates of the effects of drug use on productivity, however, are 
now thought to have over-estimated significantly (DeCew 1994). Analysis of the 2004 NDSHS found 
that one percent of the workforce reported illicit drug-related absenteeism, and 3.7 percent 
reported taking at least one day off work in the three months prior to the survey due to alcohol use 
(Pidd et al. 2008a). Employees who used illicit drugs were more likely to report absenteeism from 
illness or injury than non-drug using employees (Pidd et al. 2008b). Alcohol-related absenteeism has 
been estimated to cost between $437 million and $1.2 billion per year, and worker illnesses 
attributed to drug use to cost $2 billion annually (VicHealth 2012). 
There is a small amount of evidence surrounding the role of drugs in workplace accidents, injuries 
and fatalities, but this evidence is often methodologically limited. Some research studies (including 
international studies) have indicated that workers who engage in risky drinking are more likely to be 
involved in workplace accidents, although this research has typically needed to measure overall 
alcohol or drug consumption levels or patterns, rather than workplace impairment (Pidd and Roche 
2011). A large Australian review estimated that between 3 and 11 percent of non-fatal workplace 
injuries in Australia were associated with high-risk alcohol use (VicHealth 2012). The literature 
review conducted by NCETA concluded that while it is likely that drug use does contribute to 
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accidents, injuries and fatalities, other factors such as workload, fatigue and poor working conditions 
are likely to make greater contributions (Pidd and Roche 2011). This conclusion is consistent with 
that of an 18-month independent inquiry into workplace drug testing undertaken in the United 
Kingdom in the early 2000s (Independent Inquiry into Drug Testing at Work 2004). 
 
Effectiveness and cost effectiveness of workplace drug testing 
The available evidence from well-controlled studies on the effectiveness of drug testing in the 
workplace for improving safety is inconclusive, but there are some indications that its effectiveness 
is likely to be limited. Some studies have demonstrated a correlation between workplaces having a 
drug testing program, and reduced rates of accident or injury. However, other studies have found no 
effect or a small effect of the existence of a drug testing program on accident and injury rates. In 
general, those studies which have found limited or no correlations have been methodologically 
stronger (Pidd and Roche 2011).  
Similarly, research into the effectiveness of drug testing for reducing drug use among employees is 
limited. Several studies have demonstrated that workplaces using drug testing often see a decline 
over time in the rate of positive test results. However, there is also some evidence to indicate that 
rates of positive drug tests may not accurately reflect actual rates of drug use in the workforce 
(Walsh 2008). This suggests that declines in positive test results may be at least partly due to 
workers developing methods of evading testing or substituting specimens (Berge and Bush 2010), or 
switching to using drugs for which they will not be tested.  
Workplace drug testing is unlikely to be cost-effective for most workplaces or positions. The costs of 
employee drug testing differ depending on the type of testing used and its method of 
implementation; but similarly to the school testing costs described above, they are likely to be high. 
As well as the costs of drug testing devices and laboratory confirmations, there are costs in staff time 
to administer and take tests, training staff in test procedures, test preparation times, and costs of 
test tracking and recording. Gains from employee drug testing programs are difficult to estimate 
given the issues noted above with measuring their effects. However, cost-effectiveness studies 
conducted for programs in specific organisations or sectors have indicated that drug testing is 
unlikely to be a cost-effective way to prevent or reduce accidents, injuries, or fatalities, or to reduce 
employee drug use. For example, one program in the USA detected one drug user among 2,392 
people tested, at a cost of over $93,000 (Pidd and Roche 2011). Pidd and Roche suggest that the rate 
of drug use in the workforce may be too low for drug-testing programs to be likely to be cost-
effective. However, the cost-effectiveness of workplace drug testing may also differ for safety-
sensitive positions (Pidd and Roche 2011).  
No reliable and sufficiently relevant studies on the effectiveness of drug testing of police or others in 
positions of authority or public trust have been located.11 The cost-effectiveness of such programs is 
also likely to be very difficult to measure. 
                                                          
11
 One study indicating reduced illicit drug use among police in Afghanistan associated with drug testing has 
been published (Arfsten et al. 2012), but the context of drug use in Afghanistan prohibits making inferences 
from this result to other contexts. 
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Unintended consequences  
Workplace drug testing may have unintended negative consequences for companies and employees. 
There is little research on these consequences, but here we note some negative consequences 
which may derive from implementing drug testing programs. Surveys undertaken in the USA 
indicated that workers experienced being drug tested as humiliating, as an invasion of privacy, or as 
displaying an undeserved lack of trust by the employer (Comer 1993). A large-scale survey of 
companies with drug testing programs “reported employee resentment as a major problem” (Comer 
1993), and other studies have noted that job applicants who are drug tested may react by being less 
loyal and productive (Roche et al. 2008). Another US study found that companies with drug-testing 
programs were overall 29 per cent less productive than companies without such programs (but note 
that this study did not establish a causal relationship between drug testing and productivity) 
(Shepard and Clifton in Pidd and Roche 2011). Shepard and Clifton (1998) argue that where the type 
of program introduced is not acceptable to workers, it may reduce employee loyalty, morale and 
productivity, or have negative impacts on workplace culture or relationships between managers and 
staff.  
This is consistent with the experience of some Australian companies who have introduced drug 
testing of workers in safety-sensitive positions, which experienced problems of divisiveness in the 
workplace, particularly when management or some groups of workers have not needed to undergo 
testing (e.g. see Holland 2003). In some cases, legal or industrial action has resulted when workplace 
drug testing has been introduced. Individual employees may mount legal challenges when dismissed 
or disciplined on the basis of positive drug tests results, which carries costs for employers (and 
underscores the importance of undertaking confirmatory tests of any positive results). False 
positives could result in errors that are costly to both individuals and to companies. There have also 
been a number of industrial disputes in Australia when companies have attempted to introduce drug 
testing, with unions disputing whether and how employers can impose drug testing requirements on 
employees. These challenges can be very costly as well as disruptive of work (examples include Shell 
Refining (Australia) Pty Ltd vs CMFEU; Endeavour Energy vs Communications, Electrical, Electronic, 
Energy, Information, Postal, Plumbing and Allied Services Union of Australia and others;  South 
Blackwater Coal vs CMFEU & CEPU; Holcim Australia v Transport Workers’ Union of New South 
Wales (TWU)). 
Other negative effects, primarily for employees themselves but impacting on companies, include 
that drug testing can increase employee stress and alienation. This is obviously a negative effect in 
itself, but has also been argued to potentially contribute to increased drug use (Comer 1993). 
Workplace drug testing could also encourage employees to switch to other drugs to avoid detection. 
In Australia there are anecdotal reports of workers switching from cannabis to methamphetamine 
use, as methamphetamine has a shorter window of detection; or from cannabis to synthetic 
cannabinoids, some of which may not appear on drug tests. Such trends are of concern, since some 
drugs which have a shorter window of detection are more dangerous, and the risks of emerging 
synthetic drugs are unknown. 
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Conclusions 
Workplace drug testing violates the bodily privacy of employees, and can be considered to violate 
information privacy whenever it reveals information about an individual that is not relevant to the 
performance of his or her job. This may include drug use that occurs outside of work hours and has 
no impact on the employee’s job performance, but also the use of prescription medications, and 
other health issues. Any workplace drug testing programs in operation need to be implemented in 
such a way that this information cannot impact negatively on employees, and is stored securely and 
destroyed as appropriate.  
As discussed above, we recognise that privacy rights can be overridden by competing interests in 
some situations. In the workplace, such potentially overriding factors include efforts to ensure public 
safety, and the integrity of people in positions of public trust and authority. De facto ‘consent’ 
associated with role-specific lowered expectations of privacy may also be a factor with regard to the 
latter. But, even where workplace drug testing is justified by such factors, it may nonetheless not be 
advisable. Employers considering implementing such programs should be made aware of the current 
evidence-base on the effectiveness and cost-effectiveness of workplace drug testing programs for 
improving safety, including its high hidden costs. It is also important that such testing does not 
displace a focus on other ways of improving workplace safety, such as addressing other, reportedly 
more significant safety risk factors. These include long shifts, dirt, noise, and negative workplace 
culture or conditions. The Independent Inquiry in the United Kingdom noted evidence that the most 
effective way to improve workplace safety was likely to be improving management systems (this was 
also indicated to be the most effective way to increase productivity and reduce absenteeism), and 
that this would be far more cost-effective for many companies than drug testing programs 
(Independent Inquiry into Drug Testing at Work 2004).  
Furthermore, any drug testing programs that are introduced should be implemented in such a way 
as to minimise burdens imposed on those tested. This could include, for example, minimising the 
invasiveness of testing by careful selection of testing methods (Pidd and Roche 2011).12 Research 
undertaken at NCETA has derived a number of more specific principles for best practice for 
workplace drug testing programs. They include linking of results to counselling and assistance rather 
than punitive outcomes, allowing for employee input into the development of any drug testing 
programs, allowing for the right of appeal, and optimally, linkages to treatment and support (Pidd et 
al. 2011a). There is some evidence to indicate that testing combined with these other strategies can 
be effective, and that introducing drug testing as part of a broader strategy displaces the punitive 
focus of drug testing programs, making it more acceptable to many employees (Pidd and Roche 
2011).  
Finally, it is worth noting that while drug use can have detrimental consequences at workplaces, 
workplace culture and conditions also have important influences on the overall drug consumption of 
                                                          
12
 Oral fluid testing is often found less invasive in bodily terms. It may also be considered less invasive of 
informational privacy, due to its shorter detection windows. However, oral fluid testing is a relatively new 
technology and is currently less accurate than more invasive methods such as urinalysis or blood tests. 
Another concern with this method is that it may be less reliable for detecting some drugs (such as cannabis) 
(Moore 2012; Milman et al. 2012). Breath testing is also generally thought less invasive than other methods, 
for information on alcohol use. 
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the workforce. A limitation of workplace drug testing is that it does not address the community or 
workplace factors that might contribute to drug use; but workplaces themselves have a role to play 
in public health. For this reason the workplace has been identified as an important setting for health 
promotion practices, including interventions which aim to prevent or treat harmful drug use 
(VicHealth 2012). While drug testing programs can be very expensive for employers and could 
involve the negative unintended consequences discussed above, it may be in employers’ interests to 
introduce other measures to reduce drug use and related harms in their workforce. Ways to 
enhance access to treatment and support, health promotion programs, and web based interventions 
are all promising areas, although further evaluation of existing programs to develop future evidence-
based programs is needed (VicHealth 2012). The implementation of programs such as workplace 
counselling and support programs, enhanced access to external support, or programs to improve 
workplace culture and conditions, may be more effective than drug testing and, since they do not 
involve an infringement on privacy rights, bypass many of the problems discussed throughout this 
paper.  
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Recommendations 
1. The ANCD recommends that widespread adoption of drug testing should not occur (with the 
exception of random roadside testing for alcohol). Given the current lack of a strong evidence-
base for drug testing programs to meet the aims for which they are proposed, and since in most 
contexts drug testing involves difficult ethical and legal issues and has the potential for negative 
consequences, we recommend a general presumption against the use of drug testing, unless a 
stronger evidence-base emerges about its effectiveness. The ANCD acknowledges that there are 
uses for drug testing in some contexts, such as medical uses, or testing of workers in highly 
safety-sensitive positions in the context of a broader workplace drug strategy; but in 
considering any drug testing program, a precautionary principle should prevail. 
2. Regarding drug testing within drug treatment, there is a need to ensure that drug testing of 
people on pharmacotherapy programs is used, in collaboration with the patient, only to review 
and improve the individual’s progress in treatment. 
3. As with any procedure that is part of medical treatment, the purpose of drug testing should 
always be made clear to people who are tested in the course of receiving pharmacotherapy. 
Pharmacotherapy patients should also receive information on their rights surrounding the 
results of any positive tests and access to the results by third parties. 
4. Regarding drug testing of parents in contact with child protection services, there is a need for 
further research into how parents with drug use problems can be supported in treatment, 
including the use of drug testing where appropriate and considered as one among other 
potential screening tools. 
5. There should be a presumption against the use of drug testing programs in schools, and any 
Australian schools considering a drug testing program should be made aware of the current 
evidence-base surrounding its effectiveness and potential negative consequences, its high costs, 
and the ethical and legal issues it invokes. 
6. Evidence-based interventions for reducing drug use and related harms among school students, 
such as motivational interviewing or rigorously tested drug education programs, should be 
further developed and encouraged as more appropriate interventions for these aims than drug 
testing.  
7. Programs of drug testing welfare beneficiaries for the purposes of referral to treatment, 
deterrence, or reducing welfare spending, should not be implemented.  
8. Employers considering workplace drug testing programs should be made aware of the current 
evidence-base on the effectiveness and cost-effectiveness of workplace drug testing programs 
for improving safety, including its high hidden costs and potential adverse outcomes, and of the 
existence of other methods to improve workplace safety. 
9. Awareness that factors such as fatigue, stress, poor working conditions, and workplace culture 
play a greater role in workplace safety than does drug use, should be promoted among 
employers and employer bodies. 
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10. Where there are workplace drug testing programs, these should take all possible measures to 
minimise burdens on employees, and should follow best practice approaches including being 
accompanied by programs providing assistance, support, education and referral where 
appropriate, and being focused on rehabilitation rather than punishment. 
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